Investors File Class Action Against Fractyl Health Over Revita Results

The lawsuit, filed in the United States District Court for the Southern District of New York, represents investors who acquired Fractyl securities between January 13, 2025, and January 29, 2026. The complaint alleges that management touted the Revita system—an outpatient therapy aimed at treating type 2 diabetes and obesity—as groundbreaking while failing to disclose operational issues that compromised clinical trial results.

Scrutiny intensified on January 29, 2026, when Fractyl revealed six-month data from its REMAIN-1 Midpoint Cohort, showing more modest weight-maintenance benefits than previously suggested. During a subsequent investor call, CEO Harith Rajagopalan attributed the variance to site-specific issues, including a lack of robust dietary counseling at one location. The disclosures prompted a swift market reaction, with shares falling 68% on the day of the announcement and continuing to decline following analyst downgrades from Morgan Stanley and Canaccord Genuity.

Investors seeking to serve as lead plaintiff in the action must apply by October 20, 2026. The firm claims that Fractyl leveraged perceived success in its REMAIN-1 study to conduct public offerings in late 2025, raising millions of dollars based on disclosures that the plaintiffs contend were materially false.